Press release from Business Wire
CORRECTING and REPLACING ARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ET
<p class='bwalignc'> <i><b>To Provide An Update On Important Progress Being Made In R&D and Commercial Initiatives</b></i> </p>
Wednesday, April 03, 2013
CORRECTING and REPLACING ARIAD to Host Investor Conference Call Tomorrow, April 4th at 8:00 A.M. ET23:01 EDT Wednesday, April 03, 2013
CAMBRIDGE, Mass. (Business Wire) -- First graph, last sentence of release should read: The Company will take questions on the call. (sted The Company will not take questions on the call.)
The corrected release reads:
ARIAD TO HOST INVESTOR CONFERENCE CALL TOMORROW, APRIL 4 TH AT 8:00 A.M. ET
To Provide An Update On Important Progress Being Made In R&D and Commercial Initiatives
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will hold a conference call for the investment community tomorrow, April 4, 2013 to provide an update on its progress over the past several weeks with both its commercial launch of Iclusig™ (ponatinib) in the United States and its clinical development programs for Iclusig and AP26113. Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD, will make a statement on these and related topics. The Company will take questions on the call.
Tomorrow's Conference Call at 8:00 a.m. ET
We will hold a live webcast and conference call tomorrow morning at 8:00 a.m. ET. The live webcast can be accessed by visiting the investor relations section of the Company's website at http://investor.ariad.com. The call can be accessed by dialing 800-884-5695 (domestic) or 617-786-2960 (international) five minutes prior to the start time and providing the pass code 19013304. A replay of the call will be available on the ARIAD website approximately two hours after completion of the call and will be archived for three weeks.
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
ARIAD Pharmaceuticals, Inc.
Kendra Adams, 617-503-7028
Liza Heapes, 617-621-2315